Amphetamines work for ADHD because they raise levels of key chemical messengers in the parts of the brain responsible for focus, impulse control, and decision-making. In children with ADHD, those brain regions are underactive. A stimulant doesn’t “speed up” a hyperactive child. It boosts signaling in the specific circuits that were running too quietly, which gives the brain the resources it needs to regulate attention and behavior.
What’s Different in an ADHD Brain
ADHD is fundamentally a problem of brain signaling. The prefrontal cortex, the region behind your forehead that handles planning, prioritizing, and stopping yourself from acting on impulse, relies heavily on two chemical messengers: dopamine and norepinephrine. In children with ADHD, these messengers get cleared away from the gaps between nerve cells too quickly, before they can do their job. The result is a prefrontal cortex that struggles to keep up with the demands of sustained attention and self-control.
Brain imaging studies confirm this. When researchers use functional MRI to watch the brains of children with ADHD during tasks that require focus or inhibition, regions like the inferior frontal cortex and a deep structure called the putamen show less activation than they should. These areas are central hubs for cognitive control, and their underperformance maps directly onto the symptoms parents and teachers notice: difficulty staying on task, acting without thinking, and struggling to follow multi-step instructions.
How Amphetamines Fix the Signal
Amphetamines target the root problem by increasing the amount of dopamine and norepinephrine available between nerve cells. They do this in two ways. First, they prompt neurons to release more of these messengers. Second, they interfere with the transporter proteins (called DAT and NET) that normally vacuum dopamine and norepinephrine back into the cell. With the reuptake slowed down, the chemical signals linger longer and reach more receptors.
This matters most in the prefrontal cortex, where both transporters are active. The norepinephrine transporter in this region actually clears dopamine as well as norepinephrine, so medications that affect either transporter end up boosting both messengers in exactly the brain area that needs them. A meta-analysis of brain imaging studies found that stimulant treatment significantly increases activation in the inferior frontal cortex, the insula, and the putamen during tasks requiring inhibition and time perception. In practical terms, the underperforming circuits come online.
Why a Stimulant Calms Hyperactivity
This is the part that seems counterintuitive. If amphetamines are stimulants, why would they make a hyperactive child calmer and more focused? The answer lies in what “hyperactivity” actually is at the brain level.
One prominent explanation centers on how the brain evaluates whether a task is worth sticking with. Research published in Cell found that the largest stimulant-related changes in brain connectivity involved networks responsible for processing salience, meaning how important or rewarding something feels. The researchers hypothesized that stimulants elevate the perceived importance of mundane tasks like math homework by boosting dopamine’s effect on these salience networks. The child doesn’t gain new cognitive ability. Instead, the task starts to feel worth doing, so the brain stops seeking stimulation elsewhere through fidgeting, talking, or switching activities. The hyperactivity wasn’t excess energy. It was the brain constantly searching for something engaging enough to activate its underperforming reward and focus circuits.
This is also why stimulants produce broadly similar effects in people with and without ADHD. Anyone who takes an amphetamine will experience increased dopamine signaling. The difference is that children with ADHD start from a deficit, so the medication brings them closer to a typical baseline rather than pushing them beyond it.
What This Looks Like in Practice
Amphetamine-based medications like Adderall XR are approved for children ages six and older. Treatment typically starts at a low dose, and the prescribing doctor increases it gradually based on how the child responds. There are several approaches to this process. Some doctors prescribe a starting dose and ask parents to report back after a week or two. Others monitor more closely, increasing the dose in steps until the child shows clear improvement. In some cases, particularly in research settings, a blinded trial is used where the child receives different doses and a placebo across several weeks so that the response can be evaluated without bias from expectations.
The goal is to find the lowest dose that meaningfully reduces symptoms without causing side effects that outweigh the benefit. Parents typically notice changes in the child’s ability to sit through class, complete assignments, wait their turn, and manage frustration. Teachers are often asked to fill out rating scales during the adjustment period because they observe the child in the exact environment where ADHD symptoms cause the most difficulty.
Effects on Growth
One concern parents commonly raise is whether long-term stimulant use will affect their child’s physical development. A large qualitative review of comprehensive growth datasets found that seven out of ten studies examining height did report some decrease associated with chronic stimulant treatment, but in two of those studies the effect normalized over time. Three studies found no significant association at all. Weight showed a clearer initial dip: all studies examining weight found significant early decreases, but these also tended to normalize and sometimes reverse as treatment continued.
The overall conclusion from this body of research is that stimulant effects on growth are mainly small and transient, and clinically insignificant for most children who take the medication from childhood through adolescence and into adulthood. No clear link was found between the total duration or dose of stimulant treatment and adult height. Most studies also found that the age at which a child starts medication doesn’t predict a meaningful change in height, weight, or body mass index over the long term.
Cardiac Screening Before Starting
Amphetamines increase heart rate and blood pressure slightly, which is harmless for the vast majority of children but can pose a risk for those with undetected heart conditions. Before prescribing a stimulant, doctors are expected to take a thorough personal and family history, paying special attention to any episodes of fainting, near-fainting, or palpitations. A physical exam checks for high blood pressure, heart murmurs, and signs of connective tissue conditions that can affect heart structure.
The American Heart Association considers a baseline electrocardiogram (ECG) a reasonable step before starting medication, as it can reveal rhythm abnormalities or structural issues that wouldn’t show up on a standard physical exam. Children with known structural heart defects, cardiomyopathy, serious rhythm abnormalities, or moderate to severe high blood pressure should not take amphetamine-based medications. If any concerning findings surface during the screening, a pediatric cardiology consultation is recommended before treatment begins.